Recently, the 2019 Guangdong Manufacturing Development Annual Conference and the Guangdong Top 500 Manufacturing Enterprise Summit, co-sponsored by the Guangdong Manufacturing Association, the Guangdong Industrial Development Research Institute, and the Enterprise Competitiveness Research Center of the Guangdong Academy of Social Sciences, were held in Guangzhou. With the theme of "New Era, New Technology, New Manufacturing", the summit released the "Research Report on the Top 500 Manufacturing Enterprises in Guangdong Province in 2019" and the list of the Top 500 Manufacturing Enterprises in Guangdong Province in 2019. With its strong manufacturing strength and strong market share, Rui Pharmaceutical Co., Ltd. was successfully selected for four consecutive years (2016-2019), which is a strong recognition of Guangzhou Hairui Pharmaceutical's strength and industry contribution.

Guangzhou Hairui Pharmaceutical has always been adhering to the corporate mission of "seeking and making progress and protecting all beings", practicing the core values of "high quality, benefiting the people, innovation and perfection", and insisting that "no difficulty can bring us down, only quality" The spirit of quality is committed to providing high-quality medicines and efficient health services to the society. Facing the complicated international situation, policy changes in the pharmaceutical industry and increasing downward pressure on the economy, Guangzhou Hairui Pharmaceutical still maintains a strong momentum of development. In July 2018, Guangzhou Hairui took the lead in passing the generic drug consistency evaluation of the first anti-type 2 diabetes drug glimepiride in China, and became the first company in Guangzhou to pass the generic drug consistency evaluation. In 2019, Guangzhou Hairui's new products, such as thymosin for injection, parecoxib sodium for injection, atosiban acetate injection, and ticagrelor tablets, were successfully approved for marketing.

In the next few years, Guangzhou Hairui will continue to refine production quality, continuously improve the R&D and industrialization innovation system, focus on the R&D and industrialization of traditional Chinese medicines, chemical drugs, biological drugs, and medical devices, so as to help the steady economic growth of Guangdong Province. At the same time, Guangzhou Hairui will continue to maintain a modest and prudent style, guard against arrogance and impetuosity, closely follow the pace of the Group, implement the strategic planning goals of the Yangtze River Group during the "13th Five-Year Plan" and the next five years, adhere to reform and innovation, promote high-quality development of the enterprise, and fully Give full play to the advantages and role of "South China Terminal", strive to overfulfill the five-year plan goal, and help the Group become the most respected world-class pharmaceutical company in the health field.